A New Class of Quinazolinone Antibiotics

Staphylococcus aureus is responsible for a number of human diseases, including skin and soft tissue infections.  Annually, 292,000 hospitalizations in the US are due to S. aureus infections, of which 126,000 are related to methicillin-resistant Staphylococcus aureus (MRSA), resulting in 19,000 deaths. A novel structural class of Quinazolinone Antibiotics has been discovererd. The lead compound in this class shows high in vitro potency against Gram-positive bacteria comparable to those of linezolid and superior to vancomycin (both considered gold standards) and shows excellent in vivo activity in mouse models of MRSA infection. 
Patent Information:
For Information, Contact:
Richard Cox
Director, Technology Commercialization
University of Notre Dame
(574) 631-5158
Mayland Chang
Shahriar Mobashery
© 2018. All Rights Reserved. Powered by Inteum